Biotech News
Olema Oncology Reports Third Quarter 2026 Financial and Operating Results
On track to announce top-line data from the pivotal Phase 3 OPERA-01 trial in the first quarter of 2027 Continued strong enrollment in the pivotal Phase 3 OPERA-02 trial and the Phase 1b/2 study of OP-3136 Appointed Jason O’Byrne, MBA, as Chief Financial Officer Ended the third quarter with $413.8
